Oseltamivir
Treatment for Lower Respiratory Infections
Typical Dosage: 75 mg twice daily
Effectiveness
75%
Safety Score
65%
Clinical Trials
4
Participants
50K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
75 mg twice daily
Time to Effect
1-2 days
Treatment Duration
5 days
Evidence Quality
HIGHNumber Needed to Treat (NNT)
25(Treat 25 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
8(Treat 8 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$75
Monitoring:$150
Side Effect Mgmt:$5
Total Annual:$230
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$75,000/QALY
QALYs Gained
0.03
Outcome-Based Costs
Cost per Responder
$353.85
Cost per Remission
$920
Comparison vs Supportive Care
Cost Difference
+$75/year
More expensive
QALY Difference
+0.03 QALYs
Better outcomes
Dominance
No dominance
Oseltamivir Outcomes
for Lower Respiratory Infections
Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+65%
Remission Rate
+25%
Common Side Effects
Nausea/vomiting
+12.5%
Headache
+2.5%
Neuropsychiatric events
+0.05%
Active Clinical Trials
1 active trial recruiting for Oseltamivir in Lower Respiratory Infections
Intravenous N-acetylcysteine and Oseltamivir Versus Oseltamivir in Adults Hospitalized With Influenza and Pneumonia
NCT03900988RECRUITINGPHASE3
160 participants
INTERVENTIONAL
Hong Kong, Hong Kong
Started: May 8, 2023
Completed Clinical Trials
1 completed trial for Oseltamivir in Lower Respiratory Infections
Oseltamivir Randomised Controlled Efficacy Trial
NCT00707941COMPLETEDPHASE3
1.19K participants
INTERVENTIONAL
Dhaka, Bangladesh
Started: May 1, 2008